Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2012

Collaborative Arrangements

Revenues related to collaborative arrangements

	Three Months Ended March 31,
	2012			2011
	(in thousands)
Royalty revenues	$	32,884		$	—
Collaborative revenues:
Amortized portion of up-front payment	$	3,107		$	3,107
Milestone revenues		—			50,000
Net payment for telaprevir development costs		(1,139	)		(1,145	)
Reimbursement for manufacturing services		4,449			4,154
Total collaborative revenues attributable to the Janssen collaboration	$	6,417		$	56,116
Total revenues attributable to the Janssen collaboration	$	39,301		$	56,116

	Three Months Ended March 31,
	2012		2011
	(in thousands)
Amortized portion of up-front payments	$	9,558	$	9,558
Milestone revenues		485		1,212
Payments for manufacturing services		3,991		715
Total collaborative revenues attributable to the Mitsubishi Tanabe collaboration	$	14,034	$	11,485

Summary of activity related to net income (loss) attributable to noncontrolling interest (Alios)

	Three Months Ended March 31, 2012
	(in thousands)
Loss before provision for income taxes	$	(5,024	)
Benefit from income taxes		2,280
Change in fair value of contingent milestone and royalty payments		(970	)
Net loss attributable to noncontrolling interest (Alios)	$	(3,714	)

Summary of Alios' items included in the Company's consolidated balance sheets

	As of March 31, 2012		As of December 31, 2011
	(in thousands)
Restricted cash and cash equivalents (Alios)	$	58,017	$	51,878
Prepaid expenses and other current assets		2,318		2,299
Property and equipment, net		1,903		1,925
Intangible assets		250,600		250,600
Goodwill		4,890		4,890
Other assets		145		133
Accounts payable		1,739		4,132
Accrued expenses and other current liabilities		4,168		4,291
Accrued interest		13		13
Income taxes payable (Alios)		201		12,075
Deferred tax liability		113,840		116,121
Other liabilities		955		1,030
Redeemable noncontrolling interest (Alios)		37,496		37,036
Noncontrolling interest (Alios)		137,583		141,633